Company Description
LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments.
The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.
Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer.
The company is developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 which are preclinical candidates for the treatment of various hematologic malignancies.
LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use; and a collaboration with Merck & Co., Inc. to evaluate anti-PD-1 therapy KEYTRUDA in combination with LAVA-1207.
LAVA Therapeutics N.V. was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.
| Country | Netherlands |
| Founded | 2016 |
| IPO Date | Mar 25, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 37 |
| CEO | Stephen Allen Hurly M.B.A., M.Sc. |
Contact Details
Address: Yalelaan 62 Utrecht, P7 3584 CM Netherlands | |
| Phone | 31 6 3000 3035 |
| Website | lavatherapeutics.com |
Stock Details
| Ticker Symbol | LVTX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $15.00 |
| CIK Code | 0001840748 |
| CUSIP Number | N51517105 |
| ISIN Number | NL0015000AG6 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Stephen Allen Hurly M.B.A., M.Sc. | Chief Executive Officer, President and Executive Director |
| Fred M. Powell CPA | Chief Financial Officer |
| Dr. Hans van der Vliet M.D., Ph.D. | Chief Scientific Officer |
| Amy Garabedian J.D. | General Counsel and Corporate Secretary |
| Wouter van Hunnik | Vice President and Head of Human Resources |
| Dr. Ton Adang Ph.D. | Chief Development Officer |
| Dr. Charles Q. Morris M.D., MBChB, MRCP (UK), Ph.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 21, 2024 | 6-K | Report of foreign issuer |
| Mar 20, 2024 | 20-F | Annual and transition report of foreign private issuers |
| Mar 7, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 16, 2023 | 6-K | Report of foreign issuer |
| Nov 9, 2023 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Aug 22, 2023 | 6-K | Report of foreign issuer |
| Aug 15, 2023 | 6-K | Report of foreign issuer |
| Jun 15, 2023 | 6-K | Report of foreign issuer |
| Jun 8, 2023 | 6-K | Report of foreign issuer |